SUBSEQUENT EVENTS (Details) - Subsequent Event - Emrosi Agreement $ in Millions |
Nov. 04, 2024
USD ($)
|
|---|---|
| Subsequent Event [Line Items] | |
| Amount received from FDA under the license, collaboration, and assignment agreement | $ 15.0 |
| Period of milestone obligation to be paid off from the date of approval received | 30 days |
| Outstanding borrowings | $ 5.0 |
| X | ||||||||||
- Definition Threshold period within which the milestone obligation to be paid off from the date of approval received from FDA. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payments payable which is triggered due to approval received from FDA under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|